{"gene":"MEP1A","run_date":"2026-04-28T18:30:28","timeline":{"discoveries":[{"year":1995,"finding":"MEP1A encodes the alpha subunit of meprin A, a cell membrane oligomeric metalloendopeptidase; MEP1A maps to human chromosome 6p11-p12, and the two homologous subunit genes (MEP1A and MEP1B) are unlinked in the human genome, consistent with the mouse genome organization.","method":"Radiation hybrid mapping, somatic cell hybrid mapping, chromosomal localization","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 — direct chromosomal mapping with multiple hybrid panel methods, foundational structural characterization","pmids":["7774936"],"is_preprint":false},{"year":2000,"finding":"The human MEP1A gene spans ~45 kb, consists of 14 exons and 13 introns, and is expressed in kidney, appendix, colon, and small intestine, establishing its tissue-specific expression pattern.","method":"Genomic cloning, dot blot analysis of poly(A) RNA from 50 human tissues","journal":"Archives of biochemistry and biophysics","confidence":"Medium","confidence_rationale":"Tier 2 — direct genomic structure determination and tissue expression profiling","pmids":["10898933"],"is_preprint":false},{"year":2009,"finding":"Meprin-alpha (MEP1A) plays a protective role in intestinal inflammation; meprin-alpha knockout mice exhibited more severe intestinal injury and inflammation than wild-type mice following oral dextran sulfate sodium administration.","method":"Meprin-alpha knockout mouse model with DSS-induced colitis","journal":"Mucosal immunology","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined cellular/tissue phenotype, replicated in human genetic association","pmids":["19262505"],"is_preprint":false},{"year":2012,"finding":"TNF-α suppresses MEP1A expression through downregulation of the transcription factor CDX2; CDX2 directly binds and activates the MEP1A promoter, and TNF-α impairs CDX2-MEP1A promoter interaction, reducing MEP1A transcription.","method":"Reporter gene assays, chromatin immunoprecipitation (ChIP), RT-PCR, immunoblotting in Caco-2 cells treated with TNF-α and infliximab","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 2 — ChIP confirmed direct CDX2-MEP1A promoter interaction; multiple orthogonal methods in one study","pmids":["22326557"],"is_preprint":false},{"year":2020,"finding":"Mep1a promotes pathological cardiac remodeling by mediating ERK1/2 activation in cardiac myocytes, fibroblasts, and macrophages; Mep1a deficiency or chemical inhibition with actinonin attenuated Ang II/TAC-induced cardiac hypertrophy, fibrosis, and inflammatory cytokine (IL-6, IL-1β) production.","method":"Mep1a knockout mice with TAC/Ang II models, in vitro cardiac myocyte/fibroblast/macrophage assays, pharmacological inhibition with actinonin, ERK1/2 phosphorylation assessment","journal":"Journal of molecular and cellular cardiology","confidence":"High","confidence_rationale":"Tier 2 — genetic KO and pharmacological inhibition with defined signaling pathway (ERK1/2) and multiple cell-type-specific phenotypes","pmids":["33301800"],"is_preprint":false},{"year":2020,"finding":"Mep1a is expressed predominantly in mast cells within aortic tissue and mediates TNF-α secretion by mast cells; TNF-α from mast cells then promotes MMP2 expression and apoptosis in smooth muscle cells, driving abdominal aortic aneurysm formation and elastic lamina degradation.","method":"Mep1a knockout mice with Ang II-induced AAA model, ELISA, RT-PCR, western blotting, pharmacological inhibition with actinonin, immunohistochemistry","journal":"British journal of pharmacology","confidence":"High","confidence_rationale":"Tier 2 — genetic KO and pharmacological inhibition with defined cellular mechanism (mast cell TNF-α → SMC MMP2/apoptosis pathway)","pmids":["32072633"],"is_preprint":false},{"year":2021,"finding":"Mep1a promotes atherosclerosis and is abundantly expressed in atherosclerotic lesions but not healthy aorta; Mep1a-/- Apoe-/- mice showed significantly reduced lesion sizes, decreased necrosis, reduced plasma CXCL5, and reduced oxidative stress biomarkers, indicating Mep1a acts through modulation of oxidative stress and inflammation.","method":"Mep1a-/- Apoe-/- double knockout mouse model, lesion quantification, plasma CXCL5 measurement, oxidative stress biomarker assessment","journal":"Genetics","confidence":"High","confidence_rationale":"Tier 2 — clean double KO with multiple defined phenotypic readouts and pathway placement","pmids":["34849841"],"is_preprint":false},{"year":2023,"finding":"The lncRNA CCL14-AS suppresses MEP1A expression by interacting with MEP1A mRNA and reducing its stability; MEP1A overexpression rescued the pro-invasive phenotype in CCL14-AS-overexpressing colorectal cancer cells.","method":"RNA interaction assays, mRNA stability assays, overexpression/knockdown functional experiments (migration, wound-healing, lymph node metastasis in nude mice)","journal":"Cancer cell international","confidence":"Medium","confidence_rationale":"Tier 3 — mRNA stability mechanism supported by functional rescue but RNA interaction not fully biochemically characterized","pmids":["36793075"],"is_preprint":false}],"current_model":"MEP1A encodes meprin-alpha, a zinc metalloendopeptidase that functions at the cell membrane as an oligomeric protease; its transcription is directly activated by CDX2 and suppressed by TNF-α via CDX2 downregulation, its mRNA stability is regulated by the lncRNA CCL14-AS, and it promotes tissue remodeling and inflammation through ERK1/2 activation in cardiac cells and macrophages, TNF-α secretion by mast cells (driving MMP2 expression and smooth muscle cell apoptosis), and modulation of oxidative stress and CXCL5 in atherosclerotic lesions, while exerting a protective role in intestinal epithelial homeostasis."},"narrative":{"teleology":[{"year":1995,"claim":"Establishing that MEP1A encodes a distinct metalloendopeptidase subunit with an independent chromosomal locus resolved the structural identity of the human meprin-alpha gene and its relationship to MEP1B.","evidence":"Radiation hybrid and somatic cell hybrid mapping localized MEP1A to chromosome 6p11-p12","pmids":["7774936"],"confidence":"Medium","gaps":["No enzymatic characterization of the recombinant human protein","Oligomeric assembly mechanism not addressed","Regulatory elements unknown"]},{"year":2000,"claim":"Determining MEP1A gene structure and tissue expression revealed that the gene is restricted to kidney and intestinal tissues, providing the first framework for understanding its physiological context.","evidence":"Genomic cloning and dot blot analysis of poly(A) RNA from 50 human tissues","pmids":["10898933"],"confidence":"Medium","gaps":["Protein-level tissue expression not confirmed","Promoter elements driving tissue specificity uncharacterized","Functional role in these tissues unknown"]},{"year":2009,"claim":"Demonstrating that meprin-alpha deficiency worsens experimental colitis established a protective function for MEP1A in intestinal epithelial homeostasis, shifting the field from structural characterization to in vivo physiology.","evidence":"Meprin-alpha knockout mice subjected to DSS-induced colitis showed more severe injury and inflammation","pmids":["19262505"],"confidence":"High","gaps":["Substrate(s) mediating the protective effect not identified","Downstream signaling pathway in intestinal epithelium unknown","Whether the protective role is cell-autonomous or paracrine not resolved"]},{"year":2012,"claim":"Identifying CDX2 as a direct transcriptional activator of MEP1A and showing that TNF-α suppresses MEP1A through CDX2 downregulation linked inflammatory cytokine signaling to meprin-alpha regulation, providing a molecular explanation for reduced MEP1A in inflamed intestine.","evidence":"ChIP, reporter assays, and RT-PCR/immunoblotting in Caco-2 cells treated with TNF-α and infliximab","pmids":["22326557"],"confidence":"High","gaps":["Whether other transcription factors co-regulate MEP1A not addressed","Mechanism by which TNF-α reduces CDX2 binding not fully dissected","In vivo validation of this transcriptional axis not performed"]},{"year":2020,"claim":"Two studies revealed that MEP1A drives cardiovascular pathology through distinct cell-type-specific mechanisms — ERK1/2 activation in cardiac cells promoting hypertrophy/fibrosis, and mast-cell TNF-α secretion driving smooth muscle cell apoptosis and aortic aneurysm — demonstrating that MEP1A functions beyond the gut as a pro-inflammatory/remodeling protease in the vasculature and heart.","evidence":"Mep1a knockout and actinonin-treated mice with TAC/Ang II-induced cardiac hypertrophy and AAA models; in vitro cardiac myocyte, fibroblast, macrophage, and mast cell assays","pmids":["33301800","32072633"],"confidence":"High","gaps":["Direct proteolytic substrates activating ERK1/2 or TNF-α release not identified","Structural basis for actinonin inhibition specificity not established","Mechanism linking meprin-alpha to TNF-α processing versus secretion unclear"]},{"year":2021,"claim":"Showing that Mep1a deficiency in Apoe-null mice reduces atherosclerotic lesion size, necrosis, plasma CXCL5, and oxidative stress markers placed MEP1A as a pro-atherogenic factor and identified CXCL5 and oxidative stress as downstream effectors.","evidence":"Mep1a−/− Apoe−/− double knockout mouse model with lesion quantification and plasma biomarker analysis","pmids":["34849841"],"confidence":"High","gaps":["Whether CXCL5 is a direct proteolytic substrate of meprin-alpha not tested","Cell type responsible for meprin-alpha action in lesions not resolved beyond expression data","Therapeutic potential of meprin-alpha inhibition in atherosclerosis not evaluated"]},{"year":2023,"claim":"Discovery that the lncRNA CCL14-AS destabilizes MEP1A mRNA and that MEP1A overexpression rescues invasive phenotypes introduced a post-transcriptional regulatory layer and implicated MEP1A in colorectal cancer cell invasion.","evidence":"RNA interaction and mRNA stability assays, functional rescue experiments including lymph node metastasis in nude mice","pmids":["36793075"],"confidence":"Medium","gaps":["Direct binding site of CCL14-AS on MEP1A mRNA not mapped","Mechanism by which MEP1A promotes invasion not identified","Single-study finding not independently confirmed"]},{"year":null,"claim":"The direct proteolytic substrates of meprin-alpha that mediate its in vivo effects in both intestinal protection and cardiovascular pathology remain unidentified, and structural determinants of its oligomeric assembly and substrate selectivity are unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No substrate identified in any in vivo disease model","Structural model of human meprin-alpha oligomer unavailable","Opposing roles in gut (protective) versus vasculature (pathogenic) mechanistically unexplained"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,4,5,6]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0]}],"pathway":[],"complexes":[],"partners":["CDX2","MEP1B"],"other_free_text":[]},"mechanistic_narrative":"MEP1A encodes meprin-alpha, the alpha subunit of meprin A, a zinc metalloendopeptidase expressed predominantly in kidney and intestinal epithelia that functions as a cell-surface oligomeric protease involved in tissue remodeling and inflammatory regulation [PMID:7774936, PMID:10898933]. MEP1A transcription is directly activated by CDX2 binding to its promoter and is suppressed by TNF-α through CDX2 downregulation, while its mRNA stability is negatively regulated by the lncRNA CCL14-AS [PMID:22326557, PMID:36793075]. Loss of meprin-alpha exacerbates intestinal inflammation in DSS-colitis models, indicating a protective role in epithelial homeostasis, whereas in the cardiovascular system MEP1A promotes pathological remodeling: it drives cardiac hypertrophy and fibrosis via ERK1/2 activation, mediates mast-cell TNF-α secretion leading to smooth muscle cell apoptosis and abdominal aortic aneurysm, and enhances atherosclerotic lesion development through CXCL5 modulation and oxidative stress [PMID:19262505, PMID:33301800, PMID:32072633, PMID:34849841]."},"prefetch_data":{"uniprot":{"accession":"Q16819","full_name":"Meprin A subunit alpha","aliases":["Endopeptidase-2","N-benzoyl-L-tyrosyl-P-amino-benzoic acid hydrolase subunit alpha","PABA peptide hydrolase","PPH alpha"],"length_aa":746,"mass_kda":84.4,"function":"","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/Q16819/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MEP1A","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MEP1A","total_profiled":1310},"omim":[{"mim_id":"606635","title":"TRANSMEMBRANE PROTEASE, SERINE 15; TMPRSS15","url":"https://www.omim.org/entry/606635"},{"mim_id":"600389","title":"MEPRIN, BETA SUBUNIT; MEP1B","url":"https://www.omim.org/entry/600389"},{"mim_id":"600388","title":"MEPRIN, ALPHA SUBUNIT; MEP1A","url":"https://www.omim.org/entry/600388"},{"mim_id":"300391","title":"AMELOGENIN; AMELX","url":"https://www.omim.org/entry/300391"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":440.6}],"url":"https://www.proteinatlas.org/search/MEP1A"},"hgnc":{"alias_symbol":["PPHA"],"prev_symbol":[]},"alphafold":{"accession":"Q16819","domains":[{"cath_id":"3.40.390.10","chopping":"44-258","consensus_level":"high","plddt":92.7082,"start":44,"end":258},{"cath_id":"2.60.120.200","chopping":"266-428","consensus_level":"high","plddt":94.3813,"start":266,"end":428},{"cath_id":"2.60.210.10","chopping":"435-600","consensus_level":"high","plddt":95.709,"start":435,"end":600},{"cath_id":"-","chopping":"685-715","consensus_level":"medium","plddt":81.6455,"start":685,"end":715}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16819","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q16819-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q16819-F1-predicted_aligned_error_v6.png","plddt_mean":84.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MEP1A","jax_strain_url":"https://www.jax.org/strain/search?query=MEP1A"},"sequence":{"accession":"Q16819","fasta_url":"https://rest.uniprot.org/uniprotkb/Q16819.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q16819/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16819"}},"corpus_meta":[{"pmid":"19262505","id":"PMC_19262505","title":"MEP1A allele for meprin A metalloprotease is a susceptibility gene for inflammatory bowel disease.","date":"2009","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19262505","citation_count":59,"is_preprint":false},{"pmid":"11994164","id":"PMC_11994164","title":"The novel protein phosphatase PphA from Synechocystis PCC 6803 controls dephosphorylation of the signalling protein PII.","date":"2002","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/11994164","citation_count":52,"is_preprint":false},{"pmid":"7774936","id":"PMC_7774936","title":"The structural genes, MEP1A and MEP1B, for the alpha and beta subunits of the metalloendopeptidase meprin map to human chromosomes 6p and 18q, respectively.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7774936","citation_count":46,"is_preprint":false},{"pmid":"22326557","id":"PMC_22326557","title":"TNF-α-induced down-regulation of CDX2 suppresses MEP1A expression in colitis.","date":"2012","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/22326557","citation_count":38,"is_preprint":false},{"pmid":"16166530","id":"PMC_16166530","title":"Signal transduction protein PII phosphatase PphA is required for light-dependent control of nitrate utilization in synechocystis sp. strain PCC 6803.","date":"2005","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/16166530","citation_count":33,"is_preprint":false},{"pmid":"15817794","id":"PMC_15817794","title":"Protein phosphatase PphA from Synechocystis sp. PCC 6803: the physiological framework of PII-P dephosphorylation.","date":"2005","source":"Microbiology (Reading, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15817794","citation_count":33,"is_preprint":false},{"pmid":"33301800","id":"PMC_33301800","title":"Mep1a contributes to Ang II-induced cardiac remodeling by promoting cardiac hypertrophy, fibrosis and inflammation.","date":"2020","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/33301800","citation_count":18,"is_preprint":false},{"pmid":"7488157","id":"PMC_7488157","title":"Fine mapping of MEP1A, the gene encoding the alpha subunit of the metalloendopeptidase meprin, to human chromosome 6P21.","date":"1995","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/7488157","citation_count":17,"is_preprint":false},{"pmid":"32072633","id":"PMC_32072633","title":"Meprin-α (Mep1A) enhances TNF-α secretion by mast cells and aggravates abdominal aortic aneurysms.","date":"2020","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32072633","citation_count":12,"is_preprint":false},{"pmid":"10898933","id":"PMC_10898933","title":"Structure and expression of the human MEP1A gene encoding the alpha subunit of metalloendopeptidase meprin A.","date":"2000","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/10898933","citation_count":12,"is_preprint":false},{"pmid":"34849841","id":"PMC_34849841","title":"Identification of Mep1a as a susceptibility gene for atherosclerosis in mice.","date":"2021","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34849841","citation_count":8,"is_preprint":false},{"pmid":"31270363","id":"PMC_31270363","title":"Coordinate regulation of the expression of SdsR toxin and its downstream pphA gene by RyeA antitoxin in Escherichia coli.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31270363","citation_count":8,"is_preprint":false},{"pmid":"36793075","id":"PMC_36793075","title":"Long non-coding RNA CCL14-AS suppresses invasiveness and lymph node metastasis of colorectal cancer cells by regulating MEP1A.","date":"2023","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/36793075","citation_count":7,"is_preprint":false},{"pmid":"24388959","id":"PMC_24388959","title":"Association of MEP1A gene variants with insulin metabolism in central European women with polycystic ovary syndrome.","date":"2014","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/24388959","citation_count":5,"is_preprint":false},{"pmid":"16378686","id":"PMC_16378686","title":"Exclusion of the juvenile myoclonic epilepsy gene EFHC1 as the cause of migraine on chromosome 6, but association to two rare polymorphisms in MEP1A and RHAG.","date":"2005","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/16378686","citation_count":5,"is_preprint":false},{"pmid":"10405340","id":"PMC_10405340","title":"Identification and localization of MEP1A-like sequences (MEP1AL1-4) in the human genome.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10405340","citation_count":3,"is_preprint":false},{"pmid":"8854145","id":"PMC_8854145","title":"A HhaI polymorphism in the human MEP1A gene encoding the alpha subunit of the metalloendopeptidase meprin.","date":"1996","source":"Human heredity","url":"https://pubmed.ncbi.nlm.nih.gov/8854145","citation_count":1,"is_preprint":false},{"pmid":"40105636","id":"PMC_40105636","title":"Probing of MEP1A gene to identify biomarkers associated with post-partum anestrus in buffalo.","date":"2025","source":"Anais da Academia Brasileira de Ciencias","url":"https://pubmed.ncbi.nlm.nih.gov/40105636","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":9848,"output_tokens":1881,"usd":0.028879},"stage2":{"model":"claude-opus-4-6","input_tokens":5200,"output_tokens":4048,"usd":0.1908},"total_usd":0.219679,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"MEP1A encodes the alpha subunit of meprin A, a cell membrane oligomeric metalloendopeptidase; MEP1A maps to human chromosome 6p11-p12, and the two homologous subunit genes (MEP1A and MEP1B) are unlinked in the human genome, consistent with the mouse genome organization.\",\n      \"method\": \"Radiation hybrid mapping, somatic cell hybrid mapping, chromosomal localization\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct chromosomal mapping with multiple hybrid panel methods, foundational structural characterization\",\n      \"pmids\": [\"7774936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The human MEP1A gene spans ~45 kb, consists of 14 exons and 13 introns, and is expressed in kidney, appendix, colon, and small intestine, establishing its tissue-specific expression pattern.\",\n      \"method\": \"Genomic cloning, dot blot analysis of poly(A) RNA from 50 human tissues\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct genomic structure determination and tissue expression profiling\",\n      \"pmids\": [\"10898933\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Meprin-alpha (MEP1A) plays a protective role in intestinal inflammation; meprin-alpha knockout mice exhibited more severe intestinal injury and inflammation than wild-type mice following oral dextran sulfate sodium administration.\",\n      \"method\": \"Meprin-alpha knockout mouse model with DSS-induced colitis\",\n      \"journal\": \"Mucosal immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular/tissue phenotype, replicated in human genetic association\",\n      \"pmids\": [\"19262505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TNF-α suppresses MEP1A expression through downregulation of the transcription factor CDX2; CDX2 directly binds and activates the MEP1A promoter, and TNF-α impairs CDX2-MEP1A promoter interaction, reducing MEP1A transcription.\",\n      \"method\": \"Reporter gene assays, chromatin immunoprecipitation (ChIP), RT-PCR, immunoblotting in Caco-2 cells treated with TNF-α and infliximab\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP confirmed direct CDX2-MEP1A promoter interaction; multiple orthogonal methods in one study\",\n      \"pmids\": [\"22326557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Mep1a promotes pathological cardiac remodeling by mediating ERK1/2 activation in cardiac myocytes, fibroblasts, and macrophages; Mep1a deficiency or chemical inhibition with actinonin attenuated Ang II/TAC-induced cardiac hypertrophy, fibrosis, and inflammatory cytokine (IL-6, IL-1β) production.\",\n      \"method\": \"Mep1a knockout mice with TAC/Ang II models, in vitro cardiac myocyte/fibroblast/macrophage assays, pharmacological inhibition with actinonin, ERK1/2 phosphorylation assessment\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO and pharmacological inhibition with defined signaling pathway (ERK1/2) and multiple cell-type-specific phenotypes\",\n      \"pmids\": [\"33301800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Mep1a is expressed predominantly in mast cells within aortic tissue and mediates TNF-α secretion by mast cells; TNF-α from mast cells then promotes MMP2 expression and apoptosis in smooth muscle cells, driving abdominal aortic aneurysm formation and elastic lamina degradation.\",\n      \"method\": \"Mep1a knockout mice with Ang II-induced AAA model, ELISA, RT-PCR, western blotting, pharmacological inhibition with actinonin, immunohistochemistry\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO and pharmacological inhibition with defined cellular mechanism (mast cell TNF-α → SMC MMP2/apoptosis pathway)\",\n      \"pmids\": [\"32072633\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Mep1a promotes atherosclerosis and is abundantly expressed in atherosclerotic lesions but not healthy aorta; Mep1a-/- Apoe-/- mice showed significantly reduced lesion sizes, decreased necrosis, reduced plasma CXCL5, and reduced oxidative stress biomarkers, indicating Mep1a acts through modulation of oxidative stress and inflammation.\",\n      \"method\": \"Mep1a-/- Apoe-/- double knockout mouse model, lesion quantification, plasma CXCL5 measurement, oxidative stress biomarker assessment\",\n      \"journal\": \"Genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean double KO with multiple defined phenotypic readouts and pathway placement\",\n      \"pmids\": [\"34849841\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The lncRNA CCL14-AS suppresses MEP1A expression by interacting with MEP1A mRNA and reducing its stability; MEP1A overexpression rescued the pro-invasive phenotype in CCL14-AS-overexpressing colorectal cancer cells.\",\n      \"method\": \"RNA interaction assays, mRNA stability assays, overexpression/knockdown functional experiments (migration, wound-healing, lymph node metastasis in nude mice)\",\n      \"journal\": \"Cancer cell international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — mRNA stability mechanism supported by functional rescue but RNA interaction not fully biochemically characterized\",\n      \"pmids\": [\"36793075\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MEP1A encodes meprin-alpha, a zinc metalloendopeptidase that functions at the cell membrane as an oligomeric protease; its transcription is directly activated by CDX2 and suppressed by TNF-α via CDX2 downregulation, its mRNA stability is regulated by the lncRNA CCL14-AS, and it promotes tissue remodeling and inflammation through ERK1/2 activation in cardiac cells and macrophages, TNF-α secretion by mast cells (driving MMP2 expression and smooth muscle cell apoptosis), and modulation of oxidative stress and CXCL5 in atherosclerotic lesions, while exerting a protective role in intestinal epithelial homeostasis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"MEP1A encodes meprin-alpha, the alpha subunit of meprin A, a zinc metalloendopeptidase expressed predominantly in kidney and intestinal epithelia that functions as a cell-surface oligomeric protease involved in tissue remodeling and inflammatory regulation [PMID:7774936, PMID:10898933]. MEP1A transcription is directly activated by CDX2 binding to its promoter and is suppressed by TNF-α through CDX2 downregulation, while its mRNA stability is negatively regulated by the lncRNA CCL14-AS [PMID:22326557, PMID:36793075]. Loss of meprin-alpha exacerbates intestinal inflammation in DSS-colitis models, indicating a protective role in epithelial homeostasis, whereas in the cardiovascular system MEP1A promotes pathological remodeling: it drives cardiac hypertrophy and fibrosis via ERK1/2 activation, mediates mast-cell TNF-α secretion leading to smooth muscle cell apoptosis and abdominal aortic aneurysm, and enhances atherosclerotic lesion development through CXCL5 modulation and oxidative stress [PMID:19262505, PMID:33301800, PMID:32072633, PMID:34849841].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Establishing that MEP1A encodes a distinct metalloendopeptidase subunit with an independent chromosomal locus resolved the structural identity of the human meprin-alpha gene and its relationship to MEP1B.\",\n      \"evidence\": \"Radiation hybrid and somatic cell hybrid mapping localized MEP1A to chromosome 6p11-p12\",\n      \"pmids\": [\"7774936\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No enzymatic characterization of the recombinant human protein\", \"Oligomeric assembly mechanism not addressed\", \"Regulatory elements unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Determining MEP1A gene structure and tissue expression revealed that the gene is restricted to kidney and intestinal tissues, providing the first framework for understanding its physiological context.\",\n      \"evidence\": \"Genomic cloning and dot blot analysis of poly(A) RNA from 50 human tissues\",\n      \"pmids\": [\"10898933\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Protein-level tissue expression not confirmed\", \"Promoter elements driving tissue specificity uncharacterized\", \"Functional role in these tissues unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstrating that meprin-alpha deficiency worsens experimental colitis established a protective function for MEP1A in intestinal epithelial homeostasis, shifting the field from structural characterization to in vivo physiology.\",\n      \"evidence\": \"Meprin-alpha knockout mice subjected to DSS-induced colitis showed more severe injury and inflammation\",\n      \"pmids\": [\"19262505\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate(s) mediating the protective effect not identified\", \"Downstream signaling pathway in intestinal epithelium unknown\", \"Whether the protective role is cell-autonomous or paracrine not resolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identifying CDX2 as a direct transcriptional activator of MEP1A and showing that TNF-α suppresses MEP1A through CDX2 downregulation linked inflammatory cytokine signaling to meprin-alpha regulation, providing a molecular explanation for reduced MEP1A in inflamed intestine.\",\n      \"evidence\": \"ChIP, reporter assays, and RT-PCR/immunoblotting in Caco-2 cells treated with TNF-α and infliximab\",\n      \"pmids\": [\"22326557\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other transcription factors co-regulate MEP1A not addressed\", \"Mechanism by which TNF-α reduces CDX2 binding not fully dissected\", \"In vivo validation of this transcriptional axis not performed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Two studies revealed that MEP1A drives cardiovascular pathology through distinct cell-type-specific mechanisms — ERK1/2 activation in cardiac cells promoting hypertrophy/fibrosis, and mast-cell TNF-α secretion driving smooth muscle cell apoptosis and aortic aneurysm — demonstrating that MEP1A functions beyond the gut as a pro-inflammatory/remodeling protease in the vasculature and heart.\",\n      \"evidence\": \"Mep1a knockout and actinonin-treated mice with TAC/Ang II-induced cardiac hypertrophy and AAA models; in vitro cardiac myocyte, fibroblast, macrophage, and mast cell assays\",\n      \"pmids\": [\"33301800\", \"32072633\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct proteolytic substrates activating ERK1/2 or TNF-α release not identified\", \"Structural basis for actinonin inhibition specificity not established\", \"Mechanism linking meprin-alpha to TNF-α processing versus secretion unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showing that Mep1a deficiency in Apoe-null mice reduces atherosclerotic lesion size, necrosis, plasma CXCL5, and oxidative stress markers placed MEP1A as a pro-atherogenic factor and identified CXCL5 and oxidative stress as downstream effectors.\",\n      \"evidence\": \"Mep1a−/− Apoe−/− double knockout mouse model with lesion quantification and plasma biomarker analysis\",\n      \"pmids\": [\"34849841\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CXCL5 is a direct proteolytic substrate of meprin-alpha not tested\", \"Cell type responsible for meprin-alpha action in lesions not resolved beyond expression data\", \"Therapeutic potential of meprin-alpha inhibition in atherosclerosis not evaluated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Discovery that the lncRNA CCL14-AS destabilizes MEP1A mRNA and that MEP1A overexpression rescues invasive phenotypes introduced a post-transcriptional regulatory layer and implicated MEP1A in colorectal cancer cell invasion.\",\n      \"evidence\": \"RNA interaction and mRNA stability assays, functional rescue experiments including lymph node metastasis in nude mice\",\n      \"pmids\": [\"36793075\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding site of CCL14-AS on MEP1A mRNA not mapped\", \"Mechanism by which MEP1A promotes invasion not identified\", \"Single-study finding not independently confirmed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The direct proteolytic substrates of meprin-alpha that mediate its in vivo effects in both intestinal protection and cardiovascular pathology remain unidentified, and structural determinants of its oligomeric assembly and substrate selectivity are unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No substrate identified in any in vivo disease model\", \"Structural model of human meprin-alpha oligomer unavailable\", \"Opposing roles in gut (protective) versus vasculature (pathogenic) mechanistically unexplained\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 4, 5, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": []}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CDX2\", \"MEP1B\"],\n    \"other_free_text\": []\n  }\n}\n```\n\nWait, I need to fix the pathway slot — I used a GO term instead of a Reactome term. Let me correct.\n\n```json\n{\n  \"mechanistic_narrative\": \"MEP1A encodes meprin-alpha, the alpha subunit of meprin A, a zinc metalloendopeptidase expressed predominantly in kidney and intestinal epithelia that functions as a cell-surface oligomeric protease involved in tissue remodeling and inflammatory regulation [PMID:7774936, PMID:10898933]. MEP1A transcription is directly activated by CDX2 binding to its promoter and is suppressed by TNF-α through CDX2 downregulation, while its mRNA stability is negatively regulated by the lncRNA CCL14-AS [PMID:22326557, PMID:36793075]. Loss of meprin-alpha exacerbates intestinal inflammation in DSS-colitis models, indicating a protective role in epithelial homeostasis, whereas in the cardiovascular system MEP1A promotes pathological remodeling: it drives cardiac hypertrophy and fibrosis via ERK1/2 activation, mediates mast-cell TNF-α secretion leading to smooth muscle cell apoptosis and abdominal aortic aneurysm, and enhances atherosclerotic lesion development through CXCL5 modulation and oxidative stress [PMID:19262505, PMID:33301800, PMID:32072633, PMID:34849841].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Establishing that MEP1A encodes a distinct metalloendopeptidase subunit with an independent chromosomal locus resolved the structural identity of the human meprin-alpha gene and its relationship to MEP1B.\",\n      \"evidence\": \"Radiation hybrid and somatic cell hybrid mapping localized MEP1A to chromosome 6p11-p12\",\n      \"pmids\": [\"7774936\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No enzymatic characterization of the recombinant human protein\", \"Oligomeric assembly mechanism not addressed\", \"Regulatory elements unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Determining MEP1A gene structure and tissue expression revealed that the gene is restricted to kidney and intestinal tissues, providing the first framework for understanding its physiological context.\",\n      \"evidence\": \"Genomic cloning and dot blot analysis of poly(A) RNA from 50 human tissues\",\n      \"pmids\": [\"10898933\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Protein-level tissue expression not confirmed\", \"Promoter elements driving tissue specificity uncharacterized\", \"Functional role in these tissues unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstrating that meprin-alpha deficiency worsens experimental colitis established a protective function for MEP1A in intestinal epithelial homeostasis, shifting the field from structural characterization to in vivo physiology.\",\n      \"evidence\": \"Meprin-alpha knockout mice subjected to DSS-induced colitis showed more severe injury and inflammation\",\n      \"pmids\": [\"19262505\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate(s) mediating the protective effect not identified\", \"Downstream signaling pathway in intestinal epithelium unknown\", \"Whether the protective role is cell-autonomous or paracrine not resolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identifying CDX2 as a direct transcriptional activator of MEP1A and showing that TNF-α suppresses MEP1A through CDX2 downregulation linked inflammatory cytokine signaling to meprin-alpha regulation, providing a molecular explanation for reduced MEP1A in inflamed intestine.\",\n      \"evidence\": \"ChIP, reporter assays, and RT-PCR/immunoblotting in Caco-2 cells treated with TNF-α and infliximab\",\n      \"pmids\": [\"22326557\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other transcription factors co-regulate MEP1A not addressed\", \"Mechanism by which TNF-α reduces CDX2 binding not fully dissected\", \"In vivo validation of this transcriptional axis not performed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Two studies revealed that MEP1A drives cardiovascular pathology through distinct cell-type-specific mechanisms — ERK1/2 activation in cardiac cells promoting hypertrophy/fibrosis, and mast-cell TNF-α secretion driving smooth muscle cell apoptosis and aortic aneurysm — demonstrating that MEP1A functions beyond the gut as a pro-inflammatory/remodeling protease in the vasculature and heart.\",\n      \"evidence\": \"Mep1a knockout and actinonin-treated mice with TAC/Ang II-induced cardiac hypertrophy and AAA models; in vitro cardiac myocyte, fibroblast, macrophage, and mast cell assays\",\n      \"pmids\": [\"33301800\", \"32072633\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct proteolytic substrates activating ERK1/2 or TNF-α release not identified\", \"Structural basis for actinonin inhibition specificity not established\", \"Mechanism linking meprin-alpha to TNF-α processing versus secretion unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showing that Mep1a deficiency in Apoe-null mice reduces atherosclerotic lesion size, necrosis, plasma CXCL5, and oxidative stress markers placed MEP1A as a pro-atherogenic factor and identified CXCL5 and oxidative stress as downstream effectors.\",\n      \"evidence\": \"Mep1a−/− Apoe−/− double knockout mouse model with lesion quantification and plasma biomarker analysis\",\n      \"pmids\": [\"34849841\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CXCL5 is a direct proteolytic substrate of meprin-alpha not tested\", \"Cell type responsible for meprin-alpha action in lesions not resolved beyond expression data\", \"Therapeutic potential of meprin-alpha inhibition in atherosclerosis not evaluated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Discovery that the lncRNA CCL14-AS destabilizes MEP1A mRNA and that MEP1A overexpression rescues invasive phenotypes introduced a post-transcriptional regulatory layer and implicated MEP1A in colorectal cancer cell invasion.\",\n      \"evidence\": \"RNA interaction and mRNA stability assays, functional rescue experiments including lymph node metastasis in nude mice\",\n      \"pmids\": [\"36793075\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding site of CCL14-AS on MEP1A mRNA not mapped\", \"Mechanism by which MEP1A promotes invasion not identified\", \"Single-study finding not independently confirmed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The direct proteolytic substrates of meprin-alpha that mediate its in vivo effects in both intestinal protection and cardiovascular pathology remain unidentified, and structural determinants of its oligomeric assembly and substrate selectivity are unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No substrate identified in any in vivo disease model\", \"Structural model of human meprin-alpha oligomer unavailable\", \"Opposing roles in gut (protective) versus vasculature (pathogenic) mechanistically unexplained\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 4, 5, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 4, 5, 6]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 6]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CDX2\", \"MEP1B\"],\n    \"other_free_text\": []\n  }\n}\n```"}